INTRODUCTION: A gap remains between evidence-based guidelines in the treatment of heart failure (HF) and current pharmacologic and device therapy. The Seattle Heart Failure Model (SHFM) is an accurate predictive tool that allows the clinician to quantitatively assess the influence of pharmacologic and device therapy on HF. The authors hypothesized that graphically demonstrating the improvement in survival using such a tool may well modify physician practice behavior. METHODS: The authors examined 50 randomly selected patients from 10 primary care physicians having HF with a left ventricular ejection fraction <40%. Twenty-one data elements were entered into the SHFM to create a survival estimate before and after implementation of interventions known to be beneficial, both pharmacologic (addition of angiotensin-converting enzyme/angiotensin receptor blocker, statin, β-blocker and aldosterone blocker) and device based (consideration for automatic implantable cardioverter-defibrillator, biventricular pacer and biventricular implantable cardioverter-defibrillator). The influence of therapeutic change was presented in a focused clinical session with the primary care physician. RESULTS: The mean age of the population examined was 73 ± 10 years with New York Heart Association class 2.2 ± 0.5 symptoms. In the 50 patients examined, the authors altered device or medical therapy in 82%. This included advancement of medical therapy in 50%, consideration for device referral in 10% or both (medical therapy and device referral) in 22%. This augmentation of therapy resulted in an increase in estimated mean life expectancy from 8.8 to 10.9 years (P < 0.001). CONCLUSION: Use of the SHFM significantly impacted intensification of HF therapy in this ambulatory HF population.
INTRODUCTION: A gap remains between evidence-based guidelines in the treatment of heart failure (HF) and current pharmacologic and device therapy. The Seattle Heart Failure Model (SHFM) is an accurate predictive tool that allows the clinician to quantitatively assess the influence of pharmacologic and device therapy on HF. The authors hypothesized that graphically demonstrating the improvement in survival using such a tool may well modify physician practice behavior. METHODS: The authors examined 50 randomly selected patients from 10 primary care physicians having HF with a left ventricular ejection fraction <40%. Twenty-one data elements were entered into the SHFM to create a survival estimate before and after implementation of interventions known to be beneficial, both pharmacologic (addition of angiotensin-converting enzyme/angiotensin receptor blocker, statin, β-blocker and aldosterone blocker) and device based (consideration for automatic implantable cardioverter-defibrillator, biventricular pacer and biventricular implantable cardioverter-defibrillator). The influence of therapeutic change was presented in a focused clinical session with the primary care physician. RESULTS: The mean age of the population examined was 73 ± 10 years with New York Heart Association class 2.2 ± 0.5 symptoms. In the 50 patients examined, the authors altered device or medical therapy in 82%. This included advancement of medical therapy in 50%, consideration for device referral in 10% or both (medical therapy and device referral) in 22%. This augmentation of therapy resulted in an increase in estimated mean life expectancy from 8.8 to 10.9 years (P < 0.001). CONCLUSION: Use of the SHFM significantly impacted intensification of HF therapy in this ambulatory HF population.
Authors: Kathryn G Helmstadter; Senka Ljubojevic-Holzer; Brent M Wood; Khanha D Taheri; Simon Sedej; Jeffrey R Erickson; Julie Bossuyt; Donald M Bers Journal: Basic Res Cardiol Date: 2021-02-15 Impact factor: 17.165